Long-term Efficacy of Metacognitive Training for Depression (D-MCT)

Status Completed

Clinical Trial Summary

Aim of the current study is to investigate the long-term efficacy of Metacognitive Training for Depression (D-MCT) and to explore whether previously observed effects at the 6-month follow-up of a randomized, controlled, assessor-blind, parallel group trial are maintained at the 3-year follow-up.

Clinical Trial Description

Dissemination of treatment for depression is still unsatisfying: every second patient does not receive, refuses, or is waiting for treatment. Moreover, with a drop-out rate of almost 25% in routine clinical practice, and a 54% relapse rate for treatment responders within the two years after treatment termination, improving treatment is necessary. Metacognitive Training for depression (D-MCT), a low threshold, easy to administer group intervention was designed to fill this gap. It aims at the reduction of depressive symptoms by changing cognitive biases; not only biases targeted in cognitive behavioral therapy but also those identified by basic research. It was positively evaluated with regard to feasibility and acceptance in a non-randomized pilot study. Moreover, efficacy of D-MCT was suggested in a randomized controlled trail (RCT) in comparison to an active control intervention (Jelinek et al., in press). In this trial patients with depressive disorder were completing a psychosomatic outpatient treatment program and were randomly assigned to either D-MCT or general health training. Severity of depression and cognitive biases were assessed at baseline (t0), post treatment (t1) and 6 months (t2) later by raters blind to diagnostic status. Intention-to-treat analyses demonstrated that at the end of treatment, as well as 6 months later, improvement in depression was significantly greater in the D-MCT relative to the health training group at medium effect sizes. A significantly greater number of patients in the D-MCT group were in remission at 6-month follow-up. Moreover, the decrease in cognitive biases and increase in psychological well-being/quality of life was larger in the D-MCT than the health training group over time. Aim of the current study is to investigate the long-term efficacy of D-MCT. For this purpose, an additional 3 year follow-up assessment (t3) is conducted. The Hamilton Depression Rating Scale (HDRS, 17-item version) total score serves as the primary outcome. Self-assessed depression, dysfunctional beliefs, self-esteem, quality of life, and ability to work serve as secondary outcomes. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT02771535
Study type	Interventional
Source	Universitätsklinikum Hamburg-Eppendorf
Contact
Status	Completed
Phase	N/A
Start date	March 2016
Completion date	May 2017

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT03256162` - Ketamine as an Adjunctive Therapy for Major Depression	Phase 1
Recruiting	`NCT05570110` - Enoxolone in Major Depression - Biomarker-outcome Relationship	Phase 1/Phase 2
Completed	`NCT02530164` - Transcranial Direct Current Stimulation (tDCS) As Treatment for Major Depression	N/A
Completed	`NCT00964054` - Depression Outcomes Study of Exercise	Phase 1
Completed	`NCT01447602` - A Clinical Trial of IPT-A to Prevent Suicide in Depressed Adolescents With Suicidal Behavior	Phase 3
Completed	`NCT00517387` - The Effects of Quetiapine XR on Cognition, Mood and Anxiety Symptoms in SSRI-Resistant Unipolar Depression	Phase 3
Recruiting	`NCT04939649` - Ketamine as an Adjunctive Therapy for Major Depression (2)	Phase 3
Recruiting	`NCT05894980` - How to Reduce Suicidal Thoughts and Impulsivity in Depression	N/A
Terminated	`NCT04712968` - Efficacy of Daylight as Adjunctive Treatment in Patients With Depression	N/A
Enrolling by invitation	`NCT04717921` - Assesment of Retinal Nerve Fiber Layer in First Episode Depressive Patients Using Selective Serotonin Reuptake Inhibitor
Recruiting	`NCT03358056` - Effects of Mindfulness Based Cognitive Therapy on Emotional Processing	N/A
Recruiting	`NCT03711019` - Efficacy of Convulsive Therapies During Continuation	N/A
Completed	`NCT02104232` - Thinking Healthy Program - Peer Delivered, India (THPP-I)	N/A
Completed	`NCT02111915` - Thinking Healthy Program - Peer Delivered (Pakistan)	N/A
Terminated	`NCT01219686` - EScitalopram PIndolol ONset of Action	Phase 2/Phase 3
Completed	`NCT00158990` - Triiodothyronine (T3) Supplementation in the Treatment of Bipolar and Unipolar Depression.	Phase 3
Completed	`NCT01049347` - Amitriptyline and Paroxetine Treatment of Major Depression	Phase 3
Completed	`NCT03268434` - Evaluation of Metacognitive Training for Depression (D-MCT) in Outpatient Care	N/A
Completed	`NCT01880957` - PET and MRI Brain Imaging of Bipolar Disorder	N/A
Completed	`NCT04420793` - Voice Changes During ECT

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.